An unconventional manifestation of severe hypercholesterolemia – sudden senzorineural hearing loss? Case report
Authors:
Miriam Kozárová; Zuzana Kozelová
Authors place of work:
IV. interná klinika LF UPJŠ a UNLP Košice
Published in the journal:
AtheroRev 2023; 8(2): 112-114
Category:
Summary
There are currently several hypotheses that hearing loss may be associated with severe hypercholesterolemia, but the available literature remains ambiguous. With new estimates of the prevalence of familial hypercholesterolemia, the disease is much more common in the general population than previously thought. Although there are some exceptions, the detection rate of FH remains low, as it is still below 1 % in the most countries. At the same time, today we are witnessing the advent of a new generation of hypolipidemic drugs that bring a dramatic drop in total and LDL cholesterol and better prospects for the future, not only for patients with congenital disorders of lipid metabolism. The need for these patients to be effectively sought and treated correctly is all the greater. Limited data on the association of hypercholesterolemia with hearing impairment suggest further research in this area.
Keywords:
familial hypercholesterolemia – PCSK9 inhibitors – sudden senzorineural hearing loss
Zdroje
1. Odporúčanie hlavného odborníka na riešenie náhlej senzorineurálnej poruchy sluchu (SSNHL). Dostupné z WWW: <https://sso.sk/wp-content/ uploads/2022/01/Odporucenie-hlavneho-odbornik-na-riesenie-nahlej- senzorineuralnej-poruchy-sluchu-SSNHL.pdf>.
2. Capová Z, Varga L. Hypercholesterolémia ako rizikový faktor pre poruchu sluchu: Máme dostatok dôkazov? AtheroRev 2020; 5(1): 22–24.
3. Chang SL, Hsieh CC, Tseng KS et al. Hypercholesterolemia is correlated with an increased risk of idiopathic sudden sensorineural hearing loss: A historical prospective cohort study. Ear Hear 2014; 35(2): 256–261. Dostupné z DOI: <http://dx.doi.org/10.1097/AUD.0b013e3182a76637>.
4. Sturm AC, Knowles JW, Gidding SS et al. Convened by the Familial Hypercholesterolemia Foundation. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol 2018; 72(6): 662–680. Dostupné z DOI: <http://dx.doi.org/10.1016/j. jacc.2018.05.044>.
5. Vohnout B, Rašlová K. Familiárna hypercholesterolémia a projekt MedPed FH. Diab Obez 2019; 19(37): 8–12.
6. Representatives of the Global Familial Hypercholesterolemia Community. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol 2020; 5(2): 217–229. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2019.5173>.
7. Marcucci R, Liotta A, Cellai AP et al. Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss. J Thromb Haemost 2005; 3(5): 929–934. Dostupné z DOI: <http://dx.doi.org/10.111 1/j.1538–7836.2005.01310.x>.
8. Gratton MA, Wright CG. Alterations of inner ear morphology in experimental hypercholesterolemia. Hear Res 1992; 61(1–2): 97–105. Dostupné z DOI: <http://dx.doi.org/10.1016/0378–5955(92)90040-t>.
9. Nguyen TV, Brownell WE. Contribution of membrane cholesterol to outer hair cell lateral wall stiffness. Otolaryngol Head Neck Surg 1998; 119 (1): 14–20. Dostupné z DOI: <http://dx.doi.org/10.1016/ S0194–5998(98)70167–6>.
10. Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke 2008; 39(10): 2744–2748. Dostupné z DOI: <http://dx.doi.org/10.1161/STROKEAHA.108.519090>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2023 Číslo 2
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis